T1	PROC 47 149	Ensayo de fase II/III, multicéntrico, aleatorizado, con enmascaramiento doble y controlado con placebo
T2	PROC 155 207	evaluar la eficacia, la tolerabilidad y la seguridad
T3	Date 208 221	a largo plazo
T4	CHEM 225 238	sibeprenlimab
T6	Route 256 270	vía subcutánea
T7	LIVB 273 282	pacientes
#1	AnnotatorNotes T7	C0030705; Patients; Patient or Disabled Group
T8	DISO 287 319	nefropatía por inmunoglobulina A
#2	AnnotatorNotes T8	C0017661; IGA Glomerulonephritis; Disease or Syndrome
T9	DISO 345 361	enfermedad renal
#3	AnnotatorNotes T9	C0022658; Kidney Diseases; Disease or Syndrome | C1542676; (Renal disease NOS) or (pyoureter); Disease or Syndrome
T11	ANAT 424 431	riñones
#4	AnnotatorNotes T11	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T14	LIVB 517 524	Sujetos
#6	AnnotatorNotes T14	C0681850; Study Subject; Group
T15	Dose 566 593	al menos 20 de las 26 dosis
T16	PROC 599 605	visita
T17	Dose 651 677	al menos 9 de las 12 dosis
T18	PROC 683 689	visita
T19	Neg_cue 711 714	sin
T20	DISO 715 737	problemas de seguridad
T21	Negated 715 737	problemas de seguridad
T22	LIVB 760 772	investigador
#7	AnnotatorNotes T22	C0035173; Research Personnel; Professional or Occupational Group
T23	Spec_cue 774 781	podrían
T26	PROC 814 825	tratamiento
#8	AnnotatorNotes T26	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T27	CHEM 830 843	sibeprenlimab
T28	DISO 852 856	NIgA
T29	LIVB 864 870	sujeto
#9	AnnotatorNotes T29	C0681850; Study Subject; Group
T30	PROC 881 884	FGe
T33	PROC 993 1000	CKD-EPI
T35	PROC 1101 1114	procedimiento
T36	LIVB 1165 1187	investigador principal
#10	AnnotatorNotes T36	C1521895; Principal Investigator; Professional or Occupational Group
T37	LIVB 1267 1274	Sujetos
#11	AnnotatorNotes T37	C0681850; Study Subject; Group
T40	LIVB 1362 1369	Sujetos
#12	AnnotatorNotes T40	C0681850; Study Subject; Group
T41	DISO 1374 1390	eventos adversos
#13	AnnotatorNotes T41	C0877248; Adverse event; Pathologic Function
T42	DISO 1392 1394	EA
#14	AnnotatorNotes T42	C0002395; Alzheimer's Disease; Disease or Syndrome | C0003507; Aortic Valve Stenosis; Disease or Syndrome | C0038013; Ankylosing spondylitis; Disease or Syndrome | C0947926; Alzheimer's disease (incl subtypes); Mental or Behavioral Dysfunction
T43	PROC 1413 1424	tratamiento
#15	AnnotatorNotes T43	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T44	LIVB 1517 1529	investigador
#16	AnnotatorNotes T44	C0035173; Research Personnel; Professional or Occupational Group
T45	Neg_cue 1534 1543	impediría
T47	LIVB 1611 1617	sujeto
#17	AnnotatorNotes T47	C0681850; Study Subject; Group
T48	Neg_cue 1618 1620	no
T50	Negated 1651 1665	procedimientos
T51	LIVB 1765 1772	sujetos
#18	AnnotatorNotes T51	C0681850; Study Subject; Group
T52	Neg_cue 1794 1796	no
T54	PROC 1827 1834	visitas
T55	PROC 1840 1852	evaluaciones
#19	AnnotatorNotes T55	C1261322; Evaluation procedure; Health Care Activity
T56	PROC 1869 1891	régimen de tratamiento
T57	LIVB 1915 1929	monitor médico
T58	LIVB 1936 1948	investigador
#20	AnnotatorNotes T58	C0035173; Research Personnel; Professional or Occupational Group
T62	LIVB 1989 1995	sujeto
#21	AnnotatorNotes T62	C0681850; Study Subject; Group
T63	LIVB 2000 2007	Sujetos
#22	AnnotatorNotes T63	C0681850; Study Subject; Group
T64	PROC 2047 2065	prueba de embarazo
#23	AnnotatorNotes T64	C0032976; Pregnancy Tests; Diagnostic Procedure
T65	LIVB 2091 2113	Varones heterosexuales
T66	LIVB 2139 2161	sujetos en edad fértil
T67	Age 2150 2161	edad fértil
T68	LIVB 2169 2176	parejas
#24	AnnotatorNotes T68	C0682323; Partner in relationship; Family Group
T69	Neg_cue 2182 2184	no
T71	CHEM 2220 2235	anticonceptivos
#25	AnnotatorNotes T71	C0009871; Contraceptive Agents; Pharmacologic Substance
T72	PROC 2257 2271	consentimiento
T73	LIVB 2311 2317	sujeto
#26	AnnotatorNotes T73	C0681850; Study Subject; Group
T74	Duration 2333 2340	90 días
T75	LIVB 2354 2383	sujetos biológicos masculinos
T76	Duration 2387 2394	30 días
T77	LIVB 2396 2424	sujetos biológicos femeninos
T10	LIVB 405 416	anticuerpos
T12	DISO 456 488	Nefropatía por inmunoglobulina A
T5	PROC 928 991	fórmula de la Chronic Kidney Disease Epidemiology Collaboration
T13	Speculated 814 825	tratamiento
T24	PROC 1034 1058	consentimiento informado
T31	PROC 1547 1560	transferencia
T32	Negated 1547 1560	transferencia
T34	PROC 1491 1494	IMP
T46	PROC 1651 1665	procedimientos
T49	Speculated 830 843	sibeprenlimab
T53	Negated 1827 1834	visitas
T78	Negated 1840 1852	evaluaciones
T79	Negated 1869 1891	régimen de tratamiento
T60	PROC 2083 2086	IMP
T25	Negated 2220 2235	anticonceptivos
